A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Moderna COVID-19 vaccine reduces symptomatic infection in adults aged 18-19, Texas A&M University study shows; study finds slightly lower efficacy than other studies, with 53% effectiveness against infection, 71% against symptomatic illness

Sumitomo Pharma and Pfizer Canada announce availability of MYFEMBREE tablets in Canada; drug is available for management of moderate to severe pain from endometriosis in pre-menopausal women, management of heavy menstrual bleeding from uterine fibroids

Biogen to discontinue development and commercialization of the Alzheimer's drug ADUHELM in order to redeploy resources within the company's Alzheimer's franchise; company plans to further advance the launch of LEQEMBI in partnership with Eisai

FDA to end emergency use authorization for Paxlovid that is labeled in accordance with the EUA starting March 8, 2024; Paxlovid labeled in accordance with the drug's new drug application, approved in May 2023, is still authorized for emergency use

AstraZeneca aims to bring legal challenges to the Inflation Reduction Act due to stipulations regarding Medicare drug price negotiations; AstraZeneca’s diabetes drug Farxiga is among 10 drugs chosen for initial pricing talks

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count